Table 1.
Neoadjuvant therapy in BR/LA PDAC.
| References | Type of study | Treatment | Total no. of patients | Resectability | No. of patients | Resection rate (%) | R0 (%) | mOS (mo) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BR | LA | BR | LA | BR | LA | BR | LA | |||||
| FOLFIRINOX + RTx | ||||||||||||
| Hosein et al. (39) | Retrospective | FOLFIRINOX ± CRTx | 18 | BR/LA | 18 | 50 | 88 | x | ||||
| Boone et al. (40) | Retrospective | FOLFIRINOX ± RTx | 25 | BR/LA | 12 | 13 | 58 | 15 | 85 | 50 | x | x |
| Faris et al. (41) | Retrospective | FOLFIRINOX + CRTx | 22 | LA | 22 | 23 | 100 | x | ||||
| Christians et al. (42) | Retrospective | FOLFIRINOX + CRTx | 18 | BR | 18 | 67 | 100 | 22 | ||||
| Paniccia et al. (43) | Retrospective | FOLFIRINOX ± CRTx | 18 | BR | 18 | 85 | 100 | x | ||||
| Marthey et al. (46) | Retrospective | FOLFIRINOX ± RTx | 77 | LA/M | 77 | 36 | 89 | 22 | ||||
| Sadot et al. (48) | Retrospective | FOLFIRINOX ± CRTx | 101 | LA | 101 | 31 | 55 | 25 | ||||
| Blazer et al. (44) | Retrospective | FOLFIRINOX ± CRTx | 43 | BR/LA | 18 | 25 | 61 | 44 | 82 | 91 | 21.2 | |
| Khushman et al. (45) | Retrospective | FOLFIRINOX ± CRTx | 51 | BR/LA | 11 | 40 | 22 | 91 | 35 | |||
| Nanda et al. (47) | Retrospective | FOLFIRINOX + CRTx | 29 | BR/LA | 14 | 15 | 83 | 13 | 83 | 19 | ||
| Suker et al. (50) | Meta-analysis | FOLFIRINOX ± CRTx | 315 | LA | 315 | 26 | 74 | 24 | ||||
| Katz et al. (49) | Phase II | FOLFIRINOX + CRTx | 22 | BR | 22 | 68 | 93 | 22 | ||||
| FOLFIRINOX | ||||||||||||
| Peddi et al. (51) | Retrospective | FOLFIRINOX | 61 | BR/LA/M | 19 | 4 | 100 | 21 | x | x | x | x |
| Tinchon et al. (53) | Retrospective | FOLFIRINOX | 12 | BR | 12 | 83 | x | x | ||||
| Gunturu et al. (52) | Retrospective | FOLFIRINOX | 35 | LA/M | 16 | 13 | x | x | ||||
| Nitsche et al. (54) | Retrospective | FOLFIRINOX | 14 | LA | 14 | 29 | 75 | x | ||||
| Hackert et al. (38) | Retrospective | FOLFIRINOX | 125 | LA/M | 64 | 61 | 41 | 16 | ||||
| Yoo et al. (55) | Phase II | FOLFIRINOX | 18 | BR | 18 | 67 | 75 | 21 | ||||
| Barendoim et al. (56) | Retrospective | FOLFIRINOX | 53 | BR/LA | 23 | 30 | 87 | 10 | 100 | 100 | 28 | x |
| Byun et al. (57) | Retrospective | FOLFIRINOX | 337 | BR/LA/M | 67 | 135 | 51 | 14 | 79 | 79 | 35 | 21 |
| Rangelova et al. (35) | Retrospective | FOLFIRINOX | 154 | BR/LA | 22 | 132 | 33 | x | x | 31.9 | 21.8 | |
| GnP | ||||||||||||
| Kunzmann et al. (58) | Pilot | GnP (followed by FOLFIRINOX) | 8 | LA | 8 | 37 | 100 | x | ||||
| Reni et al. (59) | Phase I | GnP/Cape/Cis | 24 | BR/LA | 6 | 18 | 25 | 50 | 18 | |||
| Takahashi et al. (62) | Phase I | GnP + CRTx | 38 | BR | 15 | 74 | 96 | x | ||||
| Hammel et al. (60) | Phase II | GnP | 107 | LA | 107 | 15 | 44 | x | ||||
| Reni et al. (61) | Phase II | GnP (±Cape/Cis) | 54 | BR/LA | 25 | 29 | 32 | 44 | 19 | |||
| GEMCITABINE-BASED | ||||||||||||
| Lee et al. (63) | Phase II | Gem/Cape | 43 | BR/LA | 18 | 25 | 61 | 24 | 82 | 83 | 17 | |
| Katz et al. (64) | Retrospective | Gem-based + CRTx | 129 | BR | 129 | 66 | 95 | 33 | ||||
| Kim et al. (65) | Phase II | GemOx + RTx | 68 | R/BR/LA | 39 | 6 | 62 | 17 | x | x | 18 | 9 |
| Motoi et al. (66) | Phase II | Gem/S1 | 35 | R/BR | 16 | 86 | 87 | 20 | ||||
| Rose et al. (67) | Retrospective | Gem/Doc | 64 | BR | 64 | 48 | 87 | 22 | ||||
| Sherman et al. (68) | Prospective | Gem/Doc/Cape + CRTx | 45 | LA | 45 | 89 | 70 | 29 | ||||
| Hammel et al. (69) | Phase III | Gem ± Erlo ± CRTx | 442 | LA | 442 | 4 | 61 | 13 | ||||
| Fiore et al. (70) | Phase II | GemOx + CRTx | 34 | BR/LA | 7 | 27 | 55 | 100 | 22 | 14 | ||
| Busquets et al. (71) | Retrospective | GemOx ± Erlo ± CRTx | 22 | BR | 22 | 50 | 63 | 13 | ||||
| Eguchi et al. (72) | Phase II | Gem/S1 + RTx | 34 | BR/LA | 13 | 21 | 15 | 80 | 13 | 14 | ||
| Saito et al. (73) | Phase II | Gem/S1/LV | 24 | BR/LA | 21 | 3 | 61 | 93 | 22 | |||
RTx, radiotherapy; mOS (mo), median overall survival (months); BR, borderline resectable; LA, locally advanced; CRTx, chemoradiotherapy; M, metastatic disease; GnP, Gemcitabine + nab-paclitaxel; Cape, capecitabine; Cis, cisplatin; Gem, gemcitabine; CRTx, chemoradiotherapy; GemOx, gemcitabine + oxaliplatin; RTx, radiotherapy; Doc, docetaxel; Erlo, erlotinib; LV, leucovorin.